Where does Translatum Medicus Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Translatum Medicus Inc. ranks #18,216 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Translatum Medicus Inc. hold?

Translatum Medicus Inc. holds 16 US utility patents granted between 2015 and 2025, spanning 5 technology areas.

What is Translatum Medicus Inc.'s Innovation Score?

Translatum Medicus Inc. has an Innovation Score of 33.4 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Translatum Medicus Inc. focus on?

Translatum Medicus Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 14 patents, ranking #1,252 of 7,127 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Translatum Medicus Inc.'s patent grant rate increasing or decreasing?

Translatum Medicus Inc.'s recent grant velocity is +14% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Translatum Medicus Inc.'s patents?

Translatum Medicus Inc.'s patents average 15.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Translatum Medicus Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Translatum Medicus Inc.

USPTO PatentsView assignee record - 16 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Translatum ranks #18,216 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 5 technology areas.

#18,216
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.4/100): 15.1
avg claims per patent: +14%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18216 · Foreign Corporation #18,216 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #18,216/49,997
PHOTO-FINISH Torrent Pharmaceutic…
CPC-NARROW A61B · 5 areas
INNOV-THIN 33.4/100
CLAIMS-RICH 15.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +14% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Torrent Pharmaceuticals Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Translatum’s 33.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (29%) Velocity 6.7 pts (20%) Breadth 7.9 pts (24%) Claim depth 9.0 pts (27%)

Qualcomm Incorporated · highest

85
Translatum Medicus · this assignee

33
3D Lighting… · lowest

7

What this shows Translatum's Innovation Score is 33.4/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Translatum?

Each dot is one of Translatum’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Translatum’s own 15.1 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Translatum vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Translatum's grants concentrate

Translatum Medicus Inc. is a focused PatentsView assignee: 5 CPC subclasses with 87.5% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2015. By volume, Translatum sits between Torrent Pharmaceuticals Limited and Tsinghua Shenzhen International Graduate School.

Translatum's three-year grant acceleration

Translatum Medicus Inc. shows 5 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Torrent Pharmaceu…

16
Torrey Pines Inst…

16
Torshare

16
Total E&P Danmark…

16
Trilite

16
Truglo

16
Truetzschler & KG

16
Tsinghua Shenzhen…

16
Translatum Medicus ◀

16

What this shows Translatum holds 16 patents at rank #18,223, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Translatum

By rank, the assignees closest to #18,223 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Translatum's primary technology class.

Translatum's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Translatum Medicus Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.3%
2016	1	6.3%
2017	2	12.5%
2018	1	6.3%
2019	2	12.5%
2020	2	12.5%
2021	1	6.3%
2023	2	12.5%
2024	3	18.8%
2025partial year	1	6.3%

Which technologies does Translatum Medicus Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 14

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07D - Heterocyclic Compounds 2

G06T - Image Data Processing OR Generation, IN General 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Translatum Medicus Inc.'s patent record in context - here's where to go next.

Translatum Medicus Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 87.5% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #18,216 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Translatum Medicus Inc. against Torrent Pharmaceuticals Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.